Project description

Long-term effects of vaccination

In 1954, the enormous trial of Salk polio vaccine was conducted, involving 1.8 million children aged 6-10 years. The study was concentrated on proving the direct benefits for herd immunity only. No further investigation used such a huge data set to investigate the economic long-standing outcomes of the mass vaccination for economic well-being. Yet, this could bring forth strong arguments for advocating vaccination for society’s broader future welfare. The EU-funded Valvax project will study the Salk trials’ data to explain the long-term social benefits. These include
changes to household consumption, or investment behaviour that can be attributed to early childhood experience with vaccines.

**Fields of science**

- medical and health sciences > health sciences > infectious diseases > RNA viruses
- humanities > history and archaeology > history
- social sciences > economics and business > economics
- medical and health sciences > basic medicine > pharmacology and pharmacy > pharmaceutical drugs > vaccines

**Keywords**

- Salk vaccine trials
- poliomyelitis
- long-run socioeconomic effects
- non-specific effects

**Programme(s)**

- H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
- H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

**Topic(s)**

- MSCA-IF-2019 - Individual Fellowships

**Call for proposal**

- H2020-MSCA-IF-2019

See other projects for this call

**Funding Scheme**

- MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
Coordinator

SYDDANSK UNIVERSITET

Net EU contribution

€ 207 312,00

Address

Campusvej 55
5230 Odense m
Denmark

Region

Danmark > Syddanmark > Fyn

Activity type

Higher or Secondary Education Establishments

Links

Contact the organisation Website Participation in EU R&I programmes HORIZON collaboration network

Other funding

€ 0,00

EC signature date 4 March 2020
Last update: 24 July 2023

Permalink: https://cordis.europa.eu/project/id/890475

European Union, 2023